EMEA-002627-PIP01-19

Key facts

Active substance
savolitinib
Therapeutic area
Oncology
Decision number
P/0427/2019
PIP number
EMEA-002627-PIP01-19
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
Treatment of lung cancer
Route(s) of administration
Oral use
Contact for public enquiries
AstraZeneca AB (Sweden)

Tel. +46 8 55327591
E-mail: paediatrics@astrazeneca.com

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating